ISIN | LU0942225912 |
---|---|
Valor Number | 21612660 |
Bloomberg Global ID | |
Fund Name | Candriam Equities L Biotechnology R-Acc |
Fund Provider |
CANDRIAM
Serenity, Bloc - B, 19-21, route d'Arlon 8009 Strassen E-Mail: CH@Candriam.com Phone: + 352 2797-1 Web: https://www.candriam.com |
Fund Provider | CANDRIAM |
Representative in Switzerland |
CACEIS Bank, Montrouge, Zurich Branch / Switzerland Zurich Phone: +41 44 405 97 00 |
Distributor(s) | |
Asset Class | Equities |
EFC Category | |
Distribution Policy | Accumulation |
Home Country | Luxembourg |
Issuing Condition | Combination of issuing commission charged by the fund management company and transaction fee charged by the fund |
Redemption Condition | Combination of redemption commission charged by the fund management company and transaction fee charged by the fund |
Investment Strategy *** | The objective of the sub-fund is to use discretionary management to benefit from the performance of the market in global equities of companies from the biotechnology sector, and to outperform the benchmark. This sub-fund may be appropriate for investors who wish to achieve this objective over a long investment holding period and who are aware of, understand and are able to bear the specific risks of the sub-fund. |
Peculiarities |
Current Price * | 267.09 USD | 16.01.2025 |
---|---|---|
Previous Price * | 268.73 USD | 15.01.2025 |
52 Week High * | 307.14 USD | 08.11.2024 |
52 Week Low * | 248.00 USD | 19.04.2024 |
NAV * | 267.09 USD | 16.01.2025 |
Issue Price * | ||
Redemption Price * | ||
Closing Price * | ||
Indicative Minimum Price | ||
Fund Assets *** | 1,371,065,861 | |
Unit/Share Assets *** | 31,964,605 | |
Trading Information SIX |
YTD Performance | -1.42% |
31.12.2024 - 16.01.2025
31.12.2024 16.01.2025 |
---|---|---|
YTD Performance (in CHF) | -1.10% |
31.12.2024 - 16.01.2025
31.12.2024 16.01.2025 |
1 month | -4.61% |
16.12.2024 - 16.01.2025
16.12.2024 16.01.2025 |
3 months | -12.49% |
16.10.2024 - 16.01.2025
16.10.2024 16.01.2025 |
6 months | -11.22% |
16.07.2024 - 16.01.2025
16.07.2024 16.01.2025 |
1 year | -0.30% |
16.01.2024 - 16.01.2025
16.01.2024 16.01.2025 |
2 years | +7.93% |
17.01.2023 - 16.01.2025
17.01.2023 16.01.2025 |
3 years | +21.79% |
18.01.2022 - 16.01.2025
18.01.2022 16.01.2025 |
5 years | +27.56% |
16.01.2020 - 16.01.2025
16.01.2020 16.01.2025 |
Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
Gilead Sciences Inc | 5.86% | |
---|---|---|
Amgen Inc | 5.33% | |
Vertex Pharmaceuticals Inc | 5.23% | |
Regeneron Pharmaceuticals Inc | 4.68% | |
Alnylam Pharmaceuticals Inc | 4.34% | |
BioNTech SE ADR | 3.44% | |
argenx SE | 2.51% | |
Ascendis Pharma AS ADR | 2.35% | |
Insmed Inc | 2.30% | |
Neurocrine Biosciences Inc | 2.15% | |
Last data update | 30.11.2024 |
TER *** | 1.11% |
---|---|
TER date *** | 30.06.2024 |
Performance Fee *** | |
PTR | |
Max. Management Fee *** | 0.90% |
Ongoing Charges *** | 1.10% |
SRRI ***
|
|
SRRI date *** | 31.12.2024 |
Low Carbon Designation *** | |
---|---|
ESG Rating Overall *** | |
ESG Rating Corporate *** | |
ESG Rating Sovereign *** | |
% AuM H&S Controversies *** |
Avg Carbon Risk Score *** | |
---|---|
Avg Carbon Risk Cat Avg *** | |
% AuM Covered Carbon *** | |
Avg Fossil Fuel Exposure *** | |
Fossil Fuel Cat Avg *** |
Strategy Level 1 *** |
Sustainable Investment |
---|---|
Strategy Level 2 *** | |
Strategy Level 3 *** | |
Exclusions Level 1 *** | |
Exclusions Level 2 *** |